Trials / Completed
CompletedNCT01169987
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 191 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.
Conditions
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2010-07-27
- Last updated
- 2016-07-13
- Results posted
- 2016-06-14
Source: ClinicalTrials.gov record NCT01169987. Inclusion in this directory is not an endorsement.